We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $767M
1-Year Est. Return 119.71%
This Fund
S&P 500
This Quarter Est. Return
-11.74%
1 Year Est. Return
+119.71%
3 Year Est. Return
+244.81%
5 Year Est. Return
+382.5%
10 Year Est. Return
+2,655.81%
AUM
$434M
AUM Growth
-$119M
Cap. Flow
-$57.4M
Cap. Flow %
-13.21%
Top 10 Hldgs %
36.01%
Holding
127
New
20
Increased
19
Reduced
51
Closed
12

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$6.21M
2
NVMI
Nova
NVMI
+$5.21M
3
MAZE
Maze Therapeutics
MAZE
+$4.28M
4
IMVT icon
Immunovant
IMVT
+$4.07M
5
SNDX icon
Syndax Pharmaceuticals
SNDX
+$3.99M

Top Sells

Rank Stock Value
1
BBIO icon
BridgeBio Pharma
BBIO
+$18.2M
2
MSFT icon
Microsoft
MSFT
+$7.23M
3
META icon
Meta Platforms (Facebook)
META
+$7.12M
4
WIX icon
WIX.com
WIX
+$6.33M
5
MRVL icon
Marvell Technology
MRVL
+$6.16M

Sector Composition

Rank Sector Weight
1 Healthcare 73.67%
2 Technology 12.64%
3 Miscellaneous 7.93%
4 Consumer Discretionary 2.04%
5 Communication Services 2%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TEVA icon
1
Teva Pharmaceutical Industries Limited
TEVA
$45.8B
$24.2M 5.56%
1,572,181
+3,000
+0.2% +$53.6K
TLT icon
2
CALL
iShares 20+ Year Treasury Bond ETF
TLT
$47B
$23.2M 5.35%
+255,100
New +$22.7M
SNDX icon
3
Syndax Pharmaceuticals
SNDX
$1.59B
$20.4M 4.71%
1,663,974
+282,733
+20% +$3.99M
SNY icon
4
Sanofi
SNY
$103B
$16.9M 3.89%
304,515
-80,000
-21% -$4.33M
NVMI
5
Nova
NVMI
$11.1B
$16.7M 3.85%
90,697
+22,551
+33% +$5.21M
AZN icon
6
AstraZeneca
AZN
$257B
$12.9M 2.96%
87,530
-25,000
-22% -$3.62M
BBIO icon
7
BridgeBio Pharma
BBIO
$13.2B
$12.7M 2.92%
366,608
-538,671
-60% -$18.2M
SRPT icon
8
Sarepta Therapeutics
SRPT
$2.18B
$10.1M 2.32%
157,931
+59,010
+60% +$6.21M
RARE icon
9
Ultragenyx Pharmaceutical
RARE
$1.33B
$9.68M 2.23%
267,385
+38,609
+17% +$1.61M
LLY icon
10
Eli Lilly
LLY
$1.02T
$9.65M 2.22%
11,690
-1,500
-11% -$1.25M
CLDX icon
11
Celldex Therapeutics
CLDX
$3.1B
$9.22M 2.12%
507,829
+33,726
+7% +$754K
JNJ icon
12
Johnson & Johnson
JNJ
$646B
$8.76M 2.02%
52,831
-17,000
-24% -$2.66M
NVO
13
Novo Nordisk
NVO
$191B
$8.2M 1.89%
118,080
+20,000
+20% +$1.65M
ELDN icon
14
Eledon Pharmaceuticals
ELDN
$215M
$7.82M 1.8%
2,307,119
-244,500
-10% -$1.01M
MLYS icon
15
Mineralys Therapeutics
MLYS
$2.51B
$7.39M 1.7%
465,526
+274,854
+144% +$3.16M
AMZN icon
16
Amazon
AMZN
$2.71T
$6.96M 1.6%
36,607
-26,000
-42% -$5.64M
ABBV icon
17
AbbVie
ABBV
$463B
$6.34M 1.46%
30,256
-4,000
-12% -$778K
PHVS icon
18
Pharvaris
PHVS
$2.65B
$6.03M 1.39%
383,856
-4,327
-1% -$73K
ORA icon
19
Ormat Technologies
ORA
$6B
$5.94M 1.37%
84,000
+5,000
+6% +$339K
CYTK icon
20
Cytokinetics
CYTK
$9.6B
$5.83M 1.34%
144,961
-8,060
-5% -$370K
META icon
21
Meta Platforms (Facebook)
META
$1.73T
$5.74M 1.32%
9,962
-11,039
-53% -$7.12M
NVS icon
22
Novartis
NVS
$267B
$5.57M 1.28%
50,000
– –
MRK icon
23
Merck
MRK
$362B
$5.35M 1.23%
59,600
– –
PRAX icon
24
Praxis Precision Medicines
PRAX
$8.59B
$5.33M 1.23%
140,660
+49,077
+54% +$3.06M
NICE icon
25
Nice
NICE
$6.21B
$5.13M 1.18%
33,303
-9,197
-22% -$1.47M
1
2 3 4 5

Similar funds

ISWM
Independent Solutions Wealth Management Williamsville, New York $766M AUM 31.53% 1-Year Est. Return
ACP
Albar Capital Partners London, United Kingdom $767M AUM 61.96% 1-Year Est. Return
NIM
Nexus Investment Management Toronto, Ontario, Canada $767M AUM 30.97% 1-Year Est. Return
ACM
Arvin Capital Management Austin, Texas $766M AUM 36.51% 1-Year Est. Return
CBT
Crews Bank & Trust Wauchula, Florida $766M AUM 19.5% 1-Year Est. Return
SPIA
Strategic Point Investment Advisors Providence, Rhode Island $767M AUM 17.58% 1-Year Est. Return
CNB
Camden National Bank Camden, Maine $767M AUM 14.32% 1-Year Est. Return
HI
Hendershot Investments Centreville, Virginia $766M AUM 10.81% 1-Year Est. Return

Sphera Funds Management's Q1 2025 Portfolio in Review

As of Q1 2025, Sphera Funds Management held 127 positions worth $434M, down 21% from $553M the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Sphera Funds Management withdrew a net $57.4M in Q1 2025, closing 12 positions and reducing 51 holdings. Its most notable exit was Acadia Pharmaceuticals, an estimated $5.29M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 74% of assets, up from 73% a quarter earlier, followed by Technology and Miscellaneous.

Against the trend, Sphera Funds Management opened a new position in Maze Therapeutics worth $3.91M.

  • Sphera Funds Management's largest Q1 2025 buy was Maze Therapeutics: 355,554 shares worth $3.91M.
  • Sphera Funds Management added most to Sarepta Therapeutics in Q1 2025, an estimated $6.21M increase.
  • Sphera Funds Management's biggest Q1 2025 reduction was BridgeBio Pharma, cutting an estimated $18.2M.
  • Sphera Funds Management fully exited Acadia Pharmaceuticals in Q1 2025, selling an estimated $5.29M.
  • Sphera Funds Management's ten largest holdings make up 36% of its $434M portfolio in Q1 2025.
  • Sphera Funds Management opened 20 new positions and closed 12 in Q1 2025.
  • Sphera Funds Management's portfolio value fell 21% quarter-over-quarter to $434M.

Based on Sphera Funds Management's 13F filing for Q1 2025, filed 15 May 2025.